{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:02:18Z","timestamp":1789887738686,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Epileptologica"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>CSNK2B<\/jats:italic>\n                      mutations are associated with Poirier-Bienvenu neurodevelopmental syndrome (POBINDS), in which epilepsy is a common clinical feature. To describe the epilepsy phenotype of\n                      <jats:italic>CSNK2B<\/jats:italic>\n                      mutations, we reported a family with a novel\n                      <jats:italic>CSNK2B<\/jats:italic>\n                      mutation, added this information to the existing literature, and then combined these data for analysis to offer some observations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed trio-based whole-exome sequencing and Sanger validation in a family with early-onset seizures. In addition, we reviewed published reports of patients carrying pathogenic or likely pathogenic\n                      <jats:italic>CSNK2B<\/jats:italic>\n                      mutations, extracted epilepsy phenotypic data, and analyzed the correlation of epilepsy severity with the mutation type and the mutation location within the protein (specific amino acid position or domain).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified a novel pathogenic nonsense mutation in\n                      <jats:italic>CSNK2B<\/jats:italic>\n                      , c.240T\u2009&gt;\u2009G, p. Tyr80*, among three affected members of one family. Together with published cases, a total of 103 individuals with sufficient epilepsy-related data were available for analysis. Seizures occurred in 94.2% of patients, 87.4% were diagnosed with epilepsy, and seizure onset before 24 months of age in 87.2%. There were no significant differences in the incidence of seizures, epilepsy, and drug\u2011resistant epilepsy (DRE) among different mutation type groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.313, 0.069, and 0.690, respectively). Subgroup analysis of missense mutations into conservative and radical substitutions also revealed no significant differences in epilepsy and DRE incidence (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20091.000 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.714, respectively). In contrast, mutation location appeared to be more informative: mutations outside annotated protein domains showed higher epilepsy penetrance than those within domains (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.034). Exploratory analyses also suggested that the distribution of mutations across different domains varies, which may affect epilepsy severity, though further validations are required.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study expanded the mutational and phenotypic spectrum of\n                      <jats:italic>CSNK2B<\/jats:italic>\n                      -related disorders by identifying a novel pathogenic nonsense mutation. Protein-level mutation location appeared to be more informative than mutation type in relation to epilepsy severity. We noticed that the composition of intradomain mutations may play a part in predicting DRE susceptibility. Further large-scale validation studies are in need.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42494-026-00278-y","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:26:59Z","timestamp":1789885619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CSNK2B-associated epilepsy: family report and literature review"],"prefix":"10.1186","volume":"8","author":[{"given":"JiaLi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YueLin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuRong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuJing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiJuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RenKe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-3801","authenticated-orcid":false,"given":"MaoQiang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"issue":"Pt 1","key":"278_CR1","doi-asserted-by":"publisher","first-page":"146765","DOI":"10.1016\/j.ijbiomac.2025.146765","volume":"323","author":"C Borgo","year":"2025","unstructured":"Borgo C, D\u2019Amore C, Noventa F, Cesaro L, Salvi M. Regulation of the cell secretome by protein kinase CK2 modulates cell migration and extracellular matrix composition. Int J Biol Macromol. 2025;323(Pt 1):146765.","journal-title":"Int J Biol Macromol"},{"issue":"27","key":"278_CR2","doi-asserted-by":"publisher","first-page":"18394","DOI":"10.1074\/jbc.M601112200","volume":"281","author":"Y Gao","year":"2006","unstructured":"Gao Y, Wang HY. Casein kinase 2 Is activated and essential for Wnt\/beta-catenin signaling. J Biol Chem. 2006;281(27):18394\u2013400.","journal-title":"J Biol Chem"},{"key":"278_CR3","doi-asserted-by":"publisher","first-page":"850559","DOI":"10.3389\/fmolb.2022.850559","volume":"9","author":"D Ballardin","year":"2022","unstructured":"Ballardin D, Cruz-Gamero JM, Bienvenu T, Rebholz H. Comparing Two Neurodevelopmental Disorders Linked to CK2: Okur-Chung Neurodevelopmental Syndrome and Poirier-Bienvenu Neurodevelopmental Syndrome-Two Sides of the Same Coin? Front Mol Biosci. 2022;9:850559.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"278_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.7150\/ijbs.1.67","volume":"1","author":"AC Bibby","year":"2005","unstructured":"Bibby AC, Litchfield DW. The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta. Int J Biol Sci. 2005;1(2):67\u201379.","journal-title":"Int J Biol Sci"},{"issue":"7","key":"278_CR5","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1111\/epi.16931","volume":"62","author":"ME Ernst","year":"2021","unstructured":"Ernst ME, Baugh EH, Thomas A, Bier L, Lippa N, Stong N, et al. CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity. Epilepsia. 2021;62(7):e103\u20139.","journal-title":"Epilepsia"},{"issue":"6","key":"278_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1101\/gad.14.6.655","volume":"14","author":"CM Pfleger","year":"2000","unstructured":"Pfleger CM, Kirschner MW. The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1. Genes Dev. 2000;14(6):655\u201365.","journal-title":"Genes Dev"},{"key":"278_CR7","doi-asserted-by":"publisher","first-page":"892768","DOI":"10.3389\/fnins.2022.892768","volume":"16","author":"W Zhang","year":"2022","unstructured":"Zhang W, Ye F, Chen S, Peng J, Pang N, Yin F. Splicing Interruption by Intron Variants in CSNK2B Causes Poirier-Bienvenu Neurodevelopmental Syndrome: A Focus on Genotype-Phenotype Correlations. Front NeuroSci. 2022;16:892768.","journal-title":"Front NeuroSci"},{"key":"278_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.seizure.2021.10.019","volume":"93","author":"P Bonanni","year":"2021","unstructured":"Bonanni P, Baggio M, Duma GM, Negrin S, Danieli A, Giorda R. Developmental and epilepsy spectrum of Poirier-Bienvenu neurodevelopmental syndrome: Description of a new case study and review of the available literature. Seizure. 2021;93:133\u20139.","journal-title":"Seizure"},{"issue":"8","key":"278_CR9","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/humu.23270","volume":"38","author":"K Poirier","year":"2017","unstructured":"Poirier K, Hubert L, Viot G, Rio M, Billuart P, Besmond C, et al. CSNK2B splice site mutations in patients cause intellectual disability with or without myoclonic epilepsy. Hum Mutat. 2017;38(8):932\u201341.","journal-title":"Hum Mutat"},{"issue":"3","key":"278_CR10","first-page":"100111","volume":"3","author":"M Asif","year":"2022","unstructured":"Asif M, Kaygusuz E, Shinawi M, Nickelsen A, Hsieh TC, Wagle P, et al. De novo variants of CSNK2B cause a new intellectual disability-craniodigital syndrome by disrupting the canonical Wnt signaling pathway. HGG Adv. 2022;3(3):100111.","journal-title":"HGG Adv"},{"key":"278_CR11","doi-asserted-by":"publisher","first-page":"851547","DOI":"10.3389\/fmolb.2022.851547","volume":"9","author":"P Unni","year":"2022","unstructured":"Unni P, Friend J, Weinberg J, Okur V, Hochscherf J, Dominguez I. Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases. Front Mol Biosci. 2022;9:851547.","journal-title":"Front Mol Biosci"},{"key":"278_CR12","doi-asserted-by":"publisher","first-page":"811092","DOI":"10.3389\/fneur.2022.811092","volume":"13","author":"Q Yang","year":"2022","unstructured":"Yang Q, Zhang Q, Yi S, Qin Z, Shen F, Ou S, et al. De Novo CSNK2B Mutations in Five Cases of Poirier-Bienvenu Neurodevelopmental Syndrome. Front Neurol. 2022;13:811092.","journal-title":"Front Neurol"},{"issue":"1","key":"278_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41467-018-03247-3","volume":"9","author":"CP Yang","year":"2018","unstructured":"Yang CP, Li X, Wu Y, Shen Q, Zeng Y, Xiong Q, et al. Comprehensive integrative analyses identify GLT8D1 and CSNK2B as schizophrenia risk genes. Nat Commun. 2018;9(1):838.","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"278_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11010-005-3117-x","volume":"274","author":"O Blond","year":"2005","unstructured":"Blond O, Jensen HH, Buchou T, Cochet C, Issinger OG, Boldyreff B. Knocking out the regulatory beta subunit of protein kinase CK2 in mice: gene dosage effects in ES cells and embryos. Mol Cell Biochem. 2005;274(1\u20132):31\u20137.","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"278_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1128\/MCB.23.3.908-915.2003","volume":"23","author":"T Buchou","year":"2003","unstructured":"Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, Olsen BB, et al. Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol. 2003;23(3):908\u201315.","journal-title":"Mol Cell Biol"},{"key":"278_CR16","doi-asserted-by":"publisher","first-page":"967701","DOI":"10.3389\/fped.2023.967701","volume":"11","author":"X Chen","year":"2023","unstructured":"Chen X, Han Y, Li X, Huang S, Yuan H, Qin Y. Case report: Two cases of Poirier-Bienvenu neurodevelopmental syndrome and review of literature. Front Pead. 2023;11:967701.","journal-title":"Front Pead"},{"issue":"4","key":"278_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512\u201321.","journal-title":"Epilepsia"},{"key":"278_CR18","doi-asserted-by":"publisher","first-page":"801321","DOI":"10.3389\/fped.2021.801321","volume":"9","author":"R Sawires","year":"2021","unstructured":"Sawires R, Buttery J, Fahey M. A Review of Febrile Seizures: Recent Advances in Understanding of Febrile Seizure Pathophysiology and Commonly Implicated Viral Triggers. Front Pead. 2021;9:801321.","journal-title":"Front Pead"},{"issue":"6","key":"278_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069\u201377.","journal-title":"Epilepsia"},{"issue":"9","key":"278_CR20","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"1","key":"278_CR21","doi-asserted-by":"publisher","first-page":"17909","DOI":"10.1038\/s41598-019-53484-9","volume":"9","author":"J Li","year":"2019","unstructured":"Li J, Gao K, Cai S, Liu Y, Wang Y, Huang S, et al. Germline de novo variants in CSNK2B in Chinese patients with epilepsy. Sci Rep. 2019;9(1):17909.","journal-title":"Sci Rep"},{"issue":"11","key":"278_CR22","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1128\/MCB.01566-09","volume":"30","author":"E Huillard","year":"2010","unstructured":"Huillard E, Ziercher L, Blond O, Wong M, Deloulme JC, Souchelnytskyi S, et al. Disruption of CK2beta in embryonic neural stem cells compromises proliferation and oligodendrogenesis in the mouse telencephalon. Mol Cell Biol. 2010;30(11):2737\u201349.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"278_CR23","doi-asserted-by":"publisher","first-page":"e2327","DOI":"10.1002\/mgg3.2327","volume":"12","author":"D Li","year":"2024","unstructured":"Li D, Zhou B, Tian X, Chen X, Wang Y, Hao S, et al. Genetic analysis and literature review of a Poirier-Bienvenu neurodevelopmental syndrome family line caused by a de novo frameshift variant in CSNK2B. Mol Genet Genom Med. 2024;12(1):e2327.","journal-title":"Mol Genet Genom Med"},{"key":"278_CR24","doi-asserted-by":"crossref","unstructured":"Orsini A, Santangelo A, Bravin F, Bonuccelli A, Peroni D, Battini R, et al. Expanding phenotype of poirier-bienvenu syndrome: new evidence from an Italian multicentrical cohort of patients. Genes. 2022;13(2):276.","DOI":"10.3390\/genes13020276"},{"issue":"4","key":"278_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s10038-018-0559-z","volume":"64","author":"M Nakashima","year":"2019","unstructured":"Nakashima M, Tohyama J, Nakagawa E, Watanabe Y, Siew CG, Kwong CS, et al. Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures. J Hum Genet. 2019;64(4):313\u201322.","journal-title":"J Hum Genet"},{"key":"278_CR26","doi-asserted-by":"crossref","unstructured":"Di Stazio M, Zanus C, Faletra F, Pesaresi A, Ziccardi I, Morgan A, et al. Haploinsufficiency as a foreground pathomechanism of poirer-bienvenu syndrome and novel insights underlying the phenotypic continuum of CSNK2B-associated disorders. Genes. 2023;14(2):250.","DOI":"10.3390\/genes14020250"},{"issue":"31","key":"278_CR27","doi-asserted-by":"publisher","first-page":"32170","DOI":"10.1074\/jbc.M405024200","volume":"279","author":"A In\u00e1cio","year":"2004","unstructured":"In\u00e1cio A, Silva AL, Pinto J, Ji X, Morgado A, Almeida F, et al. Nonsense mutations in close proximity to the initiation codon fail to trigger full nonsense-mediated mRNA decay. J Biol Chem. 2004;279(31):32170\u201380.","journal-title":"J Biol Chem"},{"issue":"10","key":"278_CR28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/ng.3664","volume":"48","author":"RG Lindeboom","year":"2016","unstructured":"Lindeboom RG, Supek F, Lehner B. The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet. 2016;48(10):1112\u20138.","journal-title":"Nat Genet"},{"issue":"4","key":"278_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10048-021-00649-2","volume":"22","author":"S Yang","year":"2021","unstructured":"Yang S, Wu L, Liao H, Lu X, Zhang X, Kuang X, et al. Clinical and genetic analysis of six Chinese children with Poirier-Bienvenu neurodevelopmental syndrome caused by CSNK2B mutation. Neurogenetics. 2021;22(4):323\u201332.","journal-title":"Neurogenetics"},{"issue":"23","key":"278_CR30","doi-asserted-by":"publisher","first-page":"20795","DOI":"10.1074\/jbc.M301638200","volume":"278","author":"W Ahn","year":"2003","unstructured":"Ahn W, Lee MG, Kim KH, Muallem S. Multiple effects of SERCA2b mutations associated with Darier\u2019s disease. J Biol Chem. 2003;278(23):20795\u2013801.","journal-title":"J Biol Chem"},{"issue":"2\u20133","key":"278_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0163-7258(98)00064-3","volume":"82","author":"B Guerra","year":"1999","unstructured":"Guerra B, Boldyreff B, Sarno S, Cesaro L, Issinger OG, Pinna LA. CK2: a protein kinase in need of control. Pharmacol Ther. 1999;82(2\u20133):303\u201313.","journal-title":"Pharmacol Ther"},{"issue":"40","key":"278_CR32","doi-asserted-by":"publisher","first-page":"12324","DOI":"10.1021\/bi0011431","volume":"39","author":"S Sarno","year":"2000","unstructured":"Sarno S, Marin O, Boschetti M, Pagano MA, Meggio F, Pinna LA. Cooperative modulation of protein kinase CK2 by separate domains of its regulatory beta-subunit. Biochemistry. 2000;39(40):12324\u20139.","journal-title":"Biochemistry"},{"issue":"11","key":"278_CR33","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/emboj\/18.11.2930","volume":"18","author":"L Chantalat","year":"1999","unstructured":"Chantalat L, Leroy D, Filhol O, Nueda A, Benitez MJ, Chambaz EM, et al. Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger-mediated dimerization. EMBO J. 1999;18(11):2930\u201340.","journal-title":"EMBO J"},{"issue":"4154","key":"278_CR34","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1126\/science.185.4154.862","volume":"185","author":"R Grantham","year":"1974","unstructured":"Grantham R. Amino acid difference formula to help explain protein evolution. Sci (New York NY). 1974;185(4154):862\u20134.","journal-title":"Sci (New York NY)"},{"key":"278_CR35","doi-asserted-by":"publisher","unstructured":"Peka M, Balatsky V. The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex. Future Virol. 2023. https:\/\/doi.org\/10.2217\/fvl-2022-0152.","DOI":"10.2217\/fvl-2022-0152"}],"container-title":["Acta Epileptologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-026-00278-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42494-026-00278-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-026-00278-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:27:02Z","timestamp":1789885622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42494-026-00278-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1186\/s42494-026-00278-y","relation":{},"ISSN":["2096-9384","2524-4434"],"issn-type":[{"value":"2096-9384","type":"print"},{"value":"2524-4434","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from the parents or legal guardians prior to genetic testing. This study has been approved by the Biomedical Research Ethics Committee of the Affiliated Hospital of Zunyi Medical University (Ethics Approval Number: KLL-2025-636).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was taken from all patients participated in this study.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"35"}}